> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Five Additional Form 483s Posted, Including 4 From Japan
- URL: https://www.fdaweb.com/five-additional-form-483s-posted-including-4-from-japan/
- Published: 2026-11-05T21:58:00.000Z
- Updated: 2026-11-06T02:57:26.000Z
- Author: David McFarland
- Tags: enforcement

FDA 11/5 posted five additional Form FDA-483 inspection reports, including four involving manufacturers in Japan and one involving a U.S. drug outsourcing facility. The newly published records cover inspections conducted between October 2023 and September 2026\. They include:

- **LeeSar Inc., Florida:** Inspection dated September 23, 2026, involving a drug outsourcing facility. [Form FDA-483](https://www.fda.gov/media/196144/download?ref=fdaweb.com).
- **MicroBioPharm Japan Co., Ltd., Japan:** API manufacturing inspection dated February 13, 2026\. [Form FDA-483](https://www.fda.gov/media/196221/download?ref=fdaweb.com).
- **Yuki Gosei Kogyo Co., Ltd., Japan:** API manufacturing inspection dated February 6, 2026\. [Form FDA-483](https://www.fda.gov/media/196222/download?ref=fdaweb.com).
- **Nissan Chemical Corporation, Japan:** Manufacturing inspection dated November 21, 2025\. [Form FDA-483](https://www.fda.gov/media/196220/download?ref=fdaweb.com).
- **Sumitomo Osaka Cement Co., Ltd., Japan:** API manufacturing inspection dated October 27, 2023\. [Form FDA-483](https://www.fda.gov/media/196223/download?ref=fdaweb.com).

Their availability is part of the agency’s expanded transparency initiative ([see earlier story](https://www.fdaweb.com/fda-unveils-transparency-roadmap-plans-more-disclosures/)), but a significant limitation in the agency's online FOIA Electronic Reading Room makes it difficult for users to identify newly posted documents: the database does not allow records to be sorted by publication date.